Number sleven, Yes, I am aware. What I would like to have is some indication that management
is looking into this as a priority. There are many studies that are conducted in cancer trials that use
multiple drugs looking for any hint of a synergy. Pure EPA, in the right dosage, seems to affect most
any medical issue in a positive manner. Too me it seems obvious that pure EPA should be studied
as a potential adjunct drug, especially for cancer as it may end up that EPA may help with many
(if not all) various types of cancer. Just this week I heard about a "failed" cancer drug that was
used with Keytruda. There are literally hundreds of trials that are using Keytruda. Would be
encouraging to find at least one that used EPA as an adjunct drug in at least one arm of a
clinical trial of Keytruda.
Market Data 
Markets 
